Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysisLancet Oncol 2021 Oct 14;[EPub Ahead of Print], JJ Gao, J Cheng, TM Prowell, E Bloomquist, S Tang, SB Wedam, M Royce, D Krol, C Osgood, G Ison, R Sridhara, R Pazdur, JA Beaver, L Amiri-Kordestani
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.